Search in:

Advanced search

Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 10

Submit an article Journal homepage

158

Views

CrossRef citations to date

Altmetric

Drug Evaluation

LB80380: a promising new drug for the treatment of chronic hepatitis B

James Fung Teaching Consultant The University of Hong Kong, Queen Mary Hospital, Department of Medicine, Pokfulam Road, Hong Kong

, MBChB,

Ching-Lung Lai Professor The University of Hong Kong, Queen Mary Hospital, Department of Medicine, Pokfulam Road, Hong Kong

, MD &

Man-Fung Yuen Professor The University of Hong Kong, Queen Mary Hospital, Department of Medicine, Pokfulam Road, Hong Kong +852 28553984; +852 28725828; [email protected]

, MD PhD

Pages 1581-1588 | Published online: 22 Sep 2008

Cite this article
https://doi.org/10.1517/13543784.17.10.1581

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Lee W. Hepatitis B virus infection. N Engl J Med 1997;337(24):1733-45
PubMed Web of Science ®Google Scholar
Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147(1):58-61
PubMed Web of Science ®Google Scholar
Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328(7446):983
PubMed Web of Science ®Google Scholar
Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005;54(11):1610-4
PubMed Web of Science ®Google Scholar
Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347(3):168-74
PubMed Web of Science ®Google Scholar
Fung J, Yuen MF, Yuen JC, et al. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment Pharmacol Ther 2007;26(3):377-82
PubMed Web of Science ®Google Scholar
Yuen MF. Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management. J Gastroenterol Hepatol 2007;22(7):973-6
PubMed Web of Science ®Google Scholar
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295(1):65-73
PubMed Web of Science ®Google Scholar
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507-39
PubMed Web of Science ®Google Scholar
Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4(8):936-62
PubMed Web of Science ®Google Scholar
Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119(4):312-23
PubMed Web of Science ®Google Scholar
Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206-17
PubMed Web of Science ®Google Scholar
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682-95
PubMed Web of Science ®Google Scholar
Craxi A, Camma C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005;9(2):329-46, viii
PubMedGoogle Scholar
Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34(1):139-45
PubMed Web of Science ®Google Scholar
Truong BX, Seo Y, Kato M, et al. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005;16(2):279-84
PubMed Web of Science ®Google Scholar
Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46(1):45-52
PubMed Web of Science ®Google Scholar
Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339(2):61-8
PubMed Web of Science ®Google Scholar
Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17):1256-63
PubMed Web of Science ®Google Scholar
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15):1521-31
PubMed Web of Science ®Google Scholar
Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;(12):1295-303
PubMed Web of Science ®Google Scholar
Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348(9):808-16
PubMed Web of Science ®Google Scholar
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348(9):800-7
PubMed Web of Science ®Google Scholar
Pietro L, Mauro V, Elena M, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42(6):1414-9
PubMed Web of Science ®Google Scholar
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131(6):1743-51
PubMed Web of Science ®Google Scholar
Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125(2):292-7
PubMed Web of Science ®Google Scholar
Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011-20
PubMed Web of Science ®Google Scholar
Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001-10
PubMed Web of Science ®Google Scholar
Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123(6):1831-8
PubMed Web of Science ®Google Scholar
Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133(5):1437-44
PubMed Web of Science ®Google Scholar
Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008;2(1):A88-9
Google Scholar
Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129(4):1198-209
PubMed Web of Science ®Google Scholar
Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130(7):2039-49
PubMed Web of Science ®Google Scholar
Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48(9):3498-507
PubMed Web of Science ®Google Scholar
Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357(25):2576-88
PubMed Web of Science ®Google Scholar
De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 1999;12(2):81-95
PubMed Web of Science ®Google Scholar
Balzarini J, Naesens L, Herdewijn P, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989;86(1):332-6
PubMed Web of Science ®Google Scholar
De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8(5-6):261-72
PubMed Web of Science ®Google Scholar
Choi JR, Cho DG, Roh KY, et al. A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent. J Med Chem 2004;47(11):2864-9
PubMed Web of Science ®Google Scholar
Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994;140(1):1-22
PubMed Web of Science ®Google Scholar
Yuen MF, Kim J, Kim CR, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006;11(8):977-83
PubMed Web of Science ®Google Scholar
Kim J, Choi JR, Kim YZ, et al. LB80380, a novel nucleoside phophonate, is a very potent anti-HBV agent. Antivir Res 2003;57(3):A91
Google Scholar
Min CH, Kim CR, Steffy K, et al. The active metabolite of LB80380/ANA380, a novel nucleotide analog, exhibits activity in vitro against multiple clinically relevant hepatitis B virus mutants. J Hepatol 2007;46(S1):S159-60
Google Scholar
Lai CL, Han KH, Yoon SK, et al. Interim report for a phase II, multi-centre, dose-escalating study of LB80380/ANA380 in hepatitis B patients with lamivudine-resistant YMDD mutant HBV. J Hepatol 2005;42(S2):31
Google Scholar
Lai CL, Han KH, Yoon SK, et al. Phase II, multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV. J Hepatol 2006;44(S2):S5
Web of Science ®Google Scholar
Kim J, Cho WY, Cho YG, et al. In vitro and in vivo activities of LB80380: a novel acyclic phophonate nucleotide with potent anti-HBV activity [abstract no. F-1690]. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2002;42
Google Scholar
Kim GW, Roh KY, Kim J. Evaluation of mitochondrial toxicities of new phosphonate derivatives [abstract no. F-1691]. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2002;42
Google Scholar
Ho E, Lin D, Mendel D, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000;11(3):383-93
PubMed Web of Science ®Google Scholar
Cho YG, Kim GW, Kim J. Cytotoxicities of LB80317 and its derivatives in Chinese hamster ovary cells expressing human renal organic anion transporter 1 [abstract no. F-1692]. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2002;42
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

LB80380: a promising new drug for the treatment of chronic hepatitis B

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

LB80380: a promising new drug for the treatment of chronic hepatitis B

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date